In her role, Dr. Reicin will oversee all aspects of mid- to late-stage clinical development across Celgene’s drug portfolio.
Dr. Reicin most recently served as senior vice president and head of global clinical development in research and development at EMD Serono, the biopharma arm of Merck.
“Dr. Reicin is an accomplished physician with an excellent record of developing important therapeutics for multiple cancer and inflammatory indications,” said Mark Alles, chairman and CEO of Celgene. “Led by Alise, our clinical development organization will be structured to more completely align with our strategy and mission to discover, develop and commercialize innovative therapies for patients with unmet need.”
More articles on pharmacy:
20 generic drugmakers must answer price-fixing lawsuit
Novartis strikes $2.1B deal to buy cancer drugmaker Endocyte
Insys tactics to hike fentanyl sales detailed in Missouri senator’s report
